Investor's Business Daily3h agoBiohaven Stock Catapults On A Surprise FDA Move Why It Might Not Be Done RunningBiohaven stock catapulted more than 30% early Thursday after the FDA said it would review the company's embattled drug, troriluzole. SourceDisclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.Stocks